Aegerion Announces Date Of FDA Advisory Committee Review Of Lomitapide NDA

Aegerion Pharmaceuticals Inc. (AEGR)announced that the U.S. Food and Drug Administration or FDA has scheduled a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee on October 17, 2012, to review the Company's New Drug Application for lomitapide in the treatment of adult patients with Homozygous Familial Hypercholesterolemia or HoFH.

Aegerion said it is seeking authorization to market lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in adult patients with HoFH.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com